AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection
Published: 29 October 2024
-
Views:
2109
-
Likes:
7
-
Views:
2109
-
Likes:
7
-
Up Next -
6m 53s -
5m 6sPart 3 | Session 7 NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy -
5m 7s -
4m 30sPart 3 | Session 9 ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF -
3m 49s -
5m 28sPart 3 | Session 11 ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients -
3m 44sPart 3 | Session 12 BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH -
3m 40sPart 3 | Session 13 KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients -
5m 15sPart 3 | Session 14 OPTION: LAA Closure with Oral Anticoagulation after AF Ablation
-
13m 43sPart 1 View from the Thoraxcenter: AHA 24 Late-breaking Preview Joost Daemen, Nicolas M Van Mieghem
-
29m 32sPart 2 | Session 1 ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Harriette Van Spall, Kausik Ray
-
18m 41sPart 2 | Session 2 NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Harriette Van Spall, Tor Biering-Sørensen
-
17m 22sPart 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Harriette Van Spall, Milton Packer
-
16m 57sPart 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Harriette Van Spall, Katherine Tuttle
-
22m 30sPart 2 | Session 5 REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Harriette Van Spall, Mikhail Kosiborod
-
6m 17sPart 3 | Session 1 LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Dean J Kereiakes
-
3m 53sPart 3 | Session 2 LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Frederick Raal
-
7m 19sPart 3 | Session 3 Mavacamten: Real-World Experience from 22 Months of the REMS Program Milind Y Desai
-
10m 31sPart 3 | Session 4 VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Milind Y Desai
Overview
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.
- To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
- Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
- Don't miss the key take aways from our Highlights series.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Expert Interviews
Part 4
Highlights
About the episode
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.
Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).
EMPEROR-Preserved was a phase 3, randomized, double-blind trial, where patients with HFpEF receive a daily dose of either empagliflozin, a sodium–glucose cotransporter 2 inhibitor, or placebo. In this analysis, researchers hypothesized that the objective evidence of diastolic dysfunction (DD) in HFpEF could predict the response to empagliflozin. DD was defined as the presence of LAVI ≥34 mL/m2, E/e ≥13 or LVMi >115 (males) or >95 (females). Baseline echocardiographic diastolic dysfunction incrementally predicted clinical response to Empagliflozin, suggesting a targeted mechanism of action on diastolic performance.
Interview Questions:
1. What is the current research landscape for empagliflozin in treating HFpEF, and why is the trial important?
2. What was the study design and patient population of EMPEROR-Preserved?
3. What were the key findings?
4. What are the take-home messages?
5. What further research is needed in this area?
Recorded on-site at AHA Conference in Chicago, 2024.
Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Andrew JS Coats
Professor of Cardiology and Scientific Director
Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.
Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.
He is an…
Comments